Patient Experience with the SensoReady® Autoinjector Pen versus a Comparator Device: Results from a Canadian Patient Survey in Rheumatoid Arthritis and Crohn ́s Disease
DOI: https://doi.org/10.2147/ppa.s455791
2024-06-06
Patient Preference and Adherence
Abstract:Shrihari Jathanakodi, 1 Charlotte Both, 1 Ines Brueckmann, 1 Laura Rose, 2 Nahal Nasseri, 3 Jean-Pierre Raynauld, 4 Neeraj Narula 5 1 Sandoz Group AG, Holzkirchen, Germany; 2 Sandoz Inc., Princeton, NJ, USA; 3 Sandoz Canada Inc., Boucherville, QC, Canada; 4 Division of Rheumatology, Department of Medicine, Montreal Institute of Rheumatology, Université de Montréal, Montreal, QC, Canada; 5 Division of Gastroenterology, Department of Medicine, and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada Correspondence: Neeraj Narula, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada, Tel +1 905 521 2100, Email Purpose: Medication delivery device design impacts treatment satisfaction, adherence, and compliance in patients receiving biologics. This survey assessed autoinjector attributes that are important to patients, and assessed patient perceptions and preferences between an adalimumab biosimilar autoinjector (Hyrimoz ® SensoReady ® Pen [SDZ-ADL pen]) and the reference adalimumab autoinjector (Humira ® Pen [ref-ADL pen]) in patients with rheumatoid arthritis (RA) or Crohn's disease (CD) in Canada. Patients and Methods: In this survey, adult patients were recruited for web-assisted telephone interviews. Patients had ≥ 3 months' experience with the ref-ADL pen and 1– 12 months' experience with the SDZ-ADL pen. Results: The survey included 120 patients with RA (n = 32) or CD (n = 88). Mean experience with the ref-ADL pen was 7 years for RA or 5 years for CD vs 9 months with the SDZ-ADL pen. The most important autoinjector attributes were the ability to use the pen independently and the ease and simplicity of self-injection. When comparing the two autoinjectors, patients significantly preferred the SDZ-ADL pen over the ref-ADL pen for nearly every attribute evaluated, with the greatest differences reported for visual and audible feedback mechanisms, ease of self-injection, and ability to use the device independently. Overall, 82% of patients preferred the SDZ-ADL pen over the ref-ADL pen, with buttonless activation and less injection pain being the main drivers for this preference. Conclusion: Patients with RA or CD indicated a preference for the SDZ-ADL pen over the ref-ADL pen, independent of the duration of use of the pen. The preference for a biosimilar device within 1 year of switching provides reassurance of rapid patient acceptance of biosimilars and may simplify the switching process. These results confirm the importance of ensuring autoinjector design supports independent self-administration of medication and align with previous data showing high patient satisfaction with the SDZ-ADL pen. Keywords: adalimumab, adherence, autoinjector, biosimilar, patient preference Immune-mediated inflammatory diseases (IMIDs) are a diverse set of diseases, including rheumatoid arthritis (RA) and Crohn's disease (CD), with some common molecular targets for treatment. 1,2 Among these molecular targets is tumor necrosis factor-alpha (TNF-α), which has been the focus for the development of several successful disease-modifying biologics. TNF-α biologics, such as adalimumab, have been a key part of the treatment algorithms for RA and CD for several decades. 1,3 Most biologic therapies for IMIDs, including adalimumab, are delivered subcutaneously via devices such as prefilled syringes or autoinjectors, both of which allow for convenient self-administration by patients. 4,5 Previous studies have reported patient preference for autoinjectors over prefilled syringes, in terms of reduced discomfort, ease of use, and improved adherence. 6–8 Appropriate and convenient autoinjector design is essential for optimizing patient satisfaction and adherence to treatment. This can be achieved by the inclusion of autoinjector features that are optimized for self-administration while minimizing injection-site pain, as has been assessed in patient and clinician surveys and clinical studies. 5,9–13 Autoinjectors that have been developed for anti-TNF-α biologics can include features such as audible clicks to confirm the start and completion of injection, medication viewing windows, ergonomically shaped pens, and other features to improve the patient experience. 5 Some patients with IMIDs, such as those with RA or multiple sclerosis (MS), may have compromised dexterity; ease of grip and ease of operation for self-injection have been noted as important autoinjector features for patient s -Abstract Truncated-
medicine, general & internal